| 10-1074-LS(-J) - New - New |
Rockefeller University/Celldex Therapeutics |
November 2024 |
|
| 16055 NFL Delta Gly4 Env Protein Trimer, Adjuvanted with 3M-052 AF + Alum |
DAIDS/NIAID/NIH |
December 2023 |
|
| 3BNC117-LS (-J) |
Rockefeller University/Celldex Therapeutics |
November 2024 |
|
| 3M-052-AF |
Access to Advanced Health Institute (AAHI) |
November 2023 |
|
| 426c.Mod.Core-C4b, Adjuvanted |
DAIDS/NIAID/NIH |
January 2024 |
|
| AdC6-HIVgp140, AdC7-HIVgp140, CH505TF/GLA-SE Vaccines |
DAIDS/NIAID/NIH |
March 2021 |
|
| BG505 SOSIP.664 gp140 |
DAIDS/NIAID/NIH |
April 2024 |
|
| BG505 SOSIP.GT1.1 gp140 Vaccine |
International AIDS Vaccine Initiative (IAVI) |
January 2024 |
|
| CD4BS CH505M5 Pr-NP1, Adjuvanted |
DAIDS/NIAID/NIH |
April 2024 |
|
| CH505 TF chTrimer |
DAIDS/NIAID/NIH |
April 2024 |
|
| CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160 - New - New |
Duke Human Vaccine Institute (DHVI) |
November 2024 |
|
| ChAdOx1.HIVconsv62 |
University of Oxford |
May 2024 |
|
| ChAdOx1.tHIVconsv1 - New - New |
University of Oxford |
December 2024 |
|
| CMV-MVA Triplex |
City of Hope National Medical Center |
November 2023 |
|
| EnvSeq-1 and EnvSeq-2 |
DAIDS/NIAID/NIH |
October 2022 |
|
| GLA-SE |
Infectious Disease Research Institute (IDRI) |
May 2023 |
|
| GS-2872 (10-1074 LS) |
Gilead Sciences |
October 2022 |
|
| GS-5423 (3BNC117-LS) |
Gilead Sciences |
January 2023 |
|
| HIV-1 Adenovirus Type 4-Vectored (A549 cells) Vaccines (Ad4-Env150KN and Ad4-Env145NFL) |
VRC/NIAID/NIH |
July 2021 |
|
| HxB2.WT.Core-C4b, Adjuvanted |
DAIDS/NIAID/NIH |
October 2024 |
|
